Exela Pharma Sciences Llc
Exela Pharma Sciences Llc (United States) is linked to 1 FDA-registered manufacturing site. 27 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Exela Pharma Sciences Llc: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/exela-pharma-sciences-llc
Overview
Exela Pharma Sciences Llc is a pharmaceutical company headquartered in Lenoir, United States.
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Exela Pharma Sciences Llc, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
27 FDA enforcement records linked to this company.
- recall — Class II2025-09-17
Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.
- warning_letter2025-07-02
FDA Warning Letter (drug product)
- recall — Class II2025-04-02
Lack of Assurance of Sterility
- recall — Class I2023-11-29
Presence of Particulate Matter: Silicone
- recall — Class I2023-11-29
Presence of Particulate Matter: Silicone
- recall — Class I2023-11-29
Presence of Particulate Matter: Silicone
- recall — Class I2022-12-21
Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.
- recall — Class I2022-12-21
Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.
- recall — Class I2022-11-02
Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration
- recall — Class I2022-11-02
Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration
- recall — Class II2022-01-19
Lack of Assurance of Sterility
- warning_letter2021-04-09
FDA Warning Letter (drug product)
- recall — Class III2020-09-23
Short Fill
- 4832019-07-18
Containers & Closures Clean, Sterilized, Pyrogen-free
- 4832019-07-18
Cleaning / Sanitizing / Maintenance
- 4832019-07-18
Procedures for sterile drug products
- 4832019-07-18
Environmental Monitoring System
- 4832019-07-18
Investigations of discrepancies, failures
- 4832019-07-18
Validation lacking for sterile drug products
- 4832019-07-18
Prepared for each batch, include complete information
- recall — Class II2018-05-30
Labeling: Label Mix-Up: bottle labeled as Diclofenac Sodium and Misoprostol 75 mg/0.2 mg contained Diclofenac Sodium and Misoprostol 50 mg/0.2 mg tablets.
- 4832017-09-28
Environmental Monitoring System
- 4832017-09-28
Strict control not exercised over labeling issued
- 4832017-09-28
Examinations documented
- 4832017-09-28
Calibration/Inspection/Checking not done
- 4832017-09-28
Handling and Storage to Prevent Contamination
- 4832017-09-28
Drug product label, outsourcer facility
Is this Exela Pharma Sciences Llc?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.